A model-based meta-analysis of the effect of latanoprost chronotherapy on the circadian intraocular pressure of patients with glaucoma or ocular hypertension

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 4, 2010, Pages 421-425

  Luu, K T ^a   Raber, S R ^a   Nickens, D J ^a   Vicini, P ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROST;

AREA UNDER THE CURVE; ARTICLE; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; EVENING DOSAGE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; META ANALYSIS; MORNING DOSAGE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTIHYPERTENSIVE AGENTS; CIRCADIAN RHYTHM; DRUG ADMINISTRATION SCHEDULE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC;

EID: 77949874865     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.306     Document Type: Article

References (29)

1. Coleman, A.L. & Miglior, S. Risk factors for glaucoma onset and progression. Surv. Ophthalmol. 53 (suppl. 1), S3-S10 (2008).
2. Kass, M.A. et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120, 701-13; discussion 829 (2002).
3. Leske, M.C., Heijl, A., Hussein, M., Bengtsson, B., Hyman, L. & Komarof, E.; Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the efect of treatment: the early manifest glaucoma trial. Arch. Ophthalmol. 121, 48-56 (2003).
4. Alm, A. & Stjernschantz, J. Efects on intraocular pressure and side efects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 102, 1743-1752 (1995).
5. Konstas, A.G., Maltezos, A.C., Gandi, S., Hudgins, A.C. & Stewart, W.C. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am. J. Ophthalmol. 128, 15-20 (1999).
6. Konstas, A.G., Mikropoulos, D., Kaltsos, K., Jenkins, J.N. & Stewart, W.C. 24-hour intraocular pressure control obtained with evening-versus morning-dosed travoprost in primary open-angle glaucoma. Ophthalmology 113, 446-450 (2006).
7. Perry, C.M., McGavin, J.K., Culy, C.R. & Ibbotson, T. Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging 20, 597-630 (2003).
8. Xalatan, latanoprost ophthalmic solution [package insert]. New York: Pfzer, revised 2009.
9. Larsson, L.I., Mishima, H.K., Takamatsu, M., Orzalesi, N. & Rossetti, L. The efect of latanoprost on circadian intraocular pressure. Surv. Ophthalmol. 47 (suppl. 1), S90-S96 (2002).
10. Bagga, H., Liu, J.H. & Weinreb, R.N. Intraocular pressure measurements throughout the 24 h. Curr. Opin. Ophthalmol. 20, 79-83 (2009).
11. Barkana, Y., Anis, S., Liebmann, J., Tello, C. & Ritch, R. Clinical utility of intraocular pressure monitoring outside of normal ofce hours in patients with glaucoma. Arch. Ophthalmol. 124, 793-797 (2006).
12. Jonas, J.B., Budde, W., Stroux, A., Oberacher-Velten, I.M. & Jünemann, A. Single intraocular pressure measurements and diurnal intraocular pressure profles. Am. J. Ophthalmol. 139, 1136-1137 (2005).
13. Sjöquist, B., Basu, S., Byding, P., Bergh, K. & Stjernschantz, J. The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit. Drug Metab. Dispos. 26, 745-754 (1998).
14. Yan, D.B., Battista, R.A., Haidich, A.B. & Konstas, A.G. Comparison of morning versus evening dosing and 24-h post-dose efcacy of travoprost compared with latanoprost in patients with open-angle glaucoma. Curr. Med. Res. Opin. (2008); e-pub ahead of print 29 September 2008.
15. Stewart, W.C., Konstas, A.G., Nelson, L.A. & Kruft, B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efcacy of glaucoma medicines. Ophthalmology 115, 1117.el-1122.e1 (2008).
16. Ishak, K.J., Platt, R.W., Joseph, L., Hanley, J.A. & Caro, J.J. Meta-analysis of longitudinal studies. Clin. Trials 4, 525-539 (2007).
17. Liu, J.H. et al. Twenty-four-hour pattern of intraocular pressure in the aging population. Invest. Ophthalmol. Vis. Sci. 40, 2912-2917 (1999).
18. Liu, J.H., Zhang, X., Kripke, D.F. & Weinreb, R.N. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest. Ophthalmol. Vis. Sci. 44, 1586-1590 (2003).
19. Orzalesi, N., Rossetti, L., Bottoli, A., Fumagalli, E. & Fogagnolo, P. The efect of latanoprost, brimonidine, and a fxed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch. Ophthalmol. 121, 453-457 (2003).
20. Calissendorf, B., Sjöquist, B., Högberg, G. & Grunge-Lowerud, A. Bioavailability in the human eye of a fxed combination of latanoprost and timolol compared to monotherapy. J. Ocul. Pharmacol. Ther. 18, 127-131 (2002).
21. Konstas, A.G., Lake, S., Economou, A.I., Kaltsos, K., Jenkins, J.N. & Stewart, W.C. 24-Hour control with a latanoprost-timolol fxed combination vs timolol alone. Arch. Ophthalmol. 124, 1553-1557 (2006).
22. Orzalesi, N., Rossetti, L., Bottoli, A. & Fogagnolo, P. Comparison of the efects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 113, 239-246 (2006).
23. Yildirim, N., Sahin, A. & Gultekin, S. The efect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. J. Glaucoma 17, 36-39 (2008).
24. Dubiner, H.B. et al. Comparison of the diurnal ocular hypotensive efcacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin. Ther. 26, 84-91 (2004).
25. Walters, T.R., DuBiner, H.B., Carpenter, S.P., Khan, B. & VanDenburgh, A.M.; Bimatoprost Circadian IOP Study Group. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv. Ophthalmol. 49 (suppl. 1), S26-S35 (2004).
26. Savic, R.M., Jonker, D.M., Kerbusch, T. & Karlsson, M.O. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34, 711-726 (2007).
27. Chakraborty, A., Krzyzanski, W. & Jusko, W.J. Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods. J. Pharmacokinet. Biopharm. 27, 23-43 (1999).
28. Krzyzanski, W., Chakraborty, A. & Jusko, W.J. Algorithm for application of Fourier analysis for biorhythmic baselines of pharmacodynamic indirect response models. Chronobiol. Int. 17, 77-93 (2000).
29. Beal, S.L., Sheiner, L.B. & Boeckmann, A.J. NONMEM Users Guides. VI edn. (Icon Development Solutions, Ellicott City, MD, 1989-2006.